Assessment of cognition in Parkinson's disease
Assessment of cognition in Parkinson's disease
复制标题
DOI：
10.1212/01.wnl.0000091864.39702.1c
复制
发表时间：
2003-11-11
期刊：
影响因子：
9.9
通讯作者：
van Hilten, JJ
中科院分区：
文献类型：
--
作者：
Marinus, J;Visser, M;van Hilten, JJ
目的：开发一种对帕金森病（PD）中特定认知缺陷敏感的简短实用工具，用于在研究情况下比较各组，并评估认知功能随时间的变化。研究方法：进行了文献检索，以确定PD中最常受影响的认知领域，并为初始量表选择候选项目。该量表在85名患者和75名年龄、教育和性别匹配的对照组中进行了测试。符合数据质量、再现性和区分性的预定标准的项目包括在最终量表中。结果如下：最终量表SCOPA-COG（帕金森病认知结局量表）由10个项目组成，最高评分为43分，分数越高，表现越好。总分的重测信度为0.78（组内相关系数），个别项目的重测信度范围为0.40 ~ 0.75（加权Kappa）。Cronbach的α为0.83。该量表的结构效度得到了与CAMCOG（剑桥认知检查）和简易精神状态检查（MMSE）的预期相关性以及按痴呆状态分类的参与者组之间和按疾病严重程度分组的患者之间的差异的支持。该量表显示出更晚期PD患者认知评分明显降低的趋势。SCOPA-COG的变异系数高于CAMCOG或MMSE，表明更好地检测个体间差异的能力。结论：SCOPA-COG是一种简短、可靠、有效的工具，对PD患者的特异性认知功能障碍敏感。
Objective: To develop a short, practical instrument that is sensitive to the specific cognitive deficits in Parkinson's disease (PD) for comparing groups in research situations and for assessing change in cognitive functioning over time. Methods: A literature search was conducted to identify the most frequently affected cognitive domains in PD and to select candidate items for the initial scale. This scale was tested in 85 patients and 75 age-, education-, and sex-matched control subjects. Items that met predefined criteria for data quality, reproducibility, and discriminative properties were included in the final scale. Results: The final scale, the SCOPA-COG (SCales for Outcomes of PArkinson's disease-cognition), consists of 10 items with a maximum score of 43, with higher scores reflecting better performance. The test-retest reliability of the total score was 0.78 (intraclass correlation coefficient) and ranged from 0.40 to 0.75 for individual items (weighted kappa). Cronbach's alpha was 0.83. Construct validity of the scale was supported by the expected correlations with the CAMCOG (Cambridge Cognitive Examination) and the Mini-Mental State Examination (MMSE) and by differences found between groups of participants classified by dementia status and between patients grouped by disease severity. The scale showed a clear trend toward lower cognition scores for patients with more advanced PD. The coefficient of variation of the SCOPA-COG was higher than that of the CAMCOG or the MMSE, indicating a better ability to detect differences between individuals. Conclusion: The SCOPA-COG is a short, reliable, and valid instrument that is sensitive to the specific cognitive deficits in PD.